Granulosa Cell Tumor Monitoring and Treatment. Outline: 1. Surgery 2. Adjuvant 3. Chemo 4. Hormonal 5. Investigational. Whole Genome Sequencing
|
|
- Opal Knight
- 5 years ago
- Views:
Transcription
1 Potential Conflicts of Interest capped at a level befitting an academic role Lo B. Serving Two Masters 2010;362: Granulosa Cell Tumor Monitoring and Treatment Richard T. Penson, MD, MRCP Clinical Director Medical Gynecologic Oncology Genentech, Inc. Research DSMC Chair DARA BioSciences, Inc. Consultant DARA BioSciences, Inc. Research Funding MGI PHARMA, INC. Research Funding Lilly and Company. Consultant Bayer HealthCare Pharma. Research Funding GlaxoSmithKline. Scientific Advisory Board CuraGen Corporation. Research Funding PDL BioPharma, Inc. Research Funding ImClone Systems, Inc. Research Funding Abbott Laboratories. Scientific Advisory Board Endocyte, Inc. Research Funding AstraZeneca. Research Funding Eisai Inc. ResearchFunding. Genetic Aberrations in Ovarian Carcinomas Gene Amplification 1q22 RAB25 3q26 PRKCI, EVI1 and PIK3CA 5q31 FGF1 8q24 MYC 19q PIK3R1 and AKT2 20p ND 20q13.2 AURKA Gene deletion 4q, 5q, 16q, 17p, 17q, Xp&q - Gene ND Mutation (Activation) KRAS (15%) BRAF (12%) CTNNB1 (12%) CDKN2A (10%) APC (9%) PIK3CA (8%) KIT (7%) SMAD4 (7%) Loss of Heterozygosity (Inactivation) 17p13 and 17q21 (>50%) ARHI, PEG3, PLAGL1, RPS6KA2, TP53, BRCA1, BRCA2 1p, 3p, 5q, 5q, 6q, 7q and 8q (<30%) PTEN, OPCML and WWOX Bast, Hennessy, & Mills. Nature Reviews Cancer 2009;9: (Inactivation) TP53 (62%) BRCA1 (5%) BRCA2 (<5%) PTEN (3-8%) ARID1A (33-46%) New Engl J Med Hypomethylation (Activation) IGF2 and SAT2 Promoter methylation (Inactivation) ARHI, DAPK1, MLH1, ICAM1, BRCA1, BRCA2, MUC2, CDKN2A, RASSF1, SOCS1 Whole Genome Sequencing Mod. Levanon K, Crum C, Drapkin R. JCO 2008;26:
2 Forkhead Transcription Factor FOXL2 orkhead transcription factor FOXL2 N Engl J Med. 2009;360: Coffee bean nuclei Call-Exner Bodies
3 Granulosa Cell Tumor: Individualized and Personalized Care Diagnosis, Surgery and First Line Therapy Symptoms Pelvic/abd pain Urinary Bloating Early satiety Markers Abnormal US Complex Cyst >5 cm Advanced Disease Likely optimally cytoreducible Diagnostic Laparotomy Staging Diagnostic Laparotomy Debulking Adjuvant Chemotherapy Carboplatin Paclitaxel Or BEP Consider Clinical trial Intraperitoneal Chemotherapy Substituting weekly paclitaxel or docetaxel Granulosa Cell Tumor: Individualized and Personalized Care Treatment of Recurrence Rising Inhibin Potentially Platinum Resistant Rec. < 6 months Carefully consider Rx Palliative Chemotherapy Asymptomatic - Too Early Multifocal >5 cm disease - Too Late Tailor to Toxicity Consider Peg. Lipo. Doxorubicin Bevacizumab cost & risk of GIP vs. longer Gemcitabine PFS Weekly topotecan, Clinical trial Weekly paclitaxel Serous PARPi GOG 9923 Pemetrexed Endometrioid Pi3K mtor inhibitor GOG 86P Clear cell Antiangiogenic GOG 254 Mucinous GI regimen / antiangiogenic GOG 241 Low Grade MEK or b-raf inhibitor GOG 239 Advanced Disease Older Significant comorbidities Sick Stage IV Neoadjuvant Chemotherapy Carboplatin Paclitaxel or Carboplatin If responding If not Interval Cytoreduction Personalize Care Potentially Platinum Sensitive Rec. > 6 months Platinum based Combination Chemotherapy Options Secondary Cytoreduction IF Few mets and pt Fit Carboplatin and Peg. Lipo. Doxorubicin or Gemcitabine or Weekly Paclitaxel Clinical Trial and monitoring
4 CA-125 MUC1, 16, other mucins in gel Modified Gendler 2001
5
6 GOG RTM 0602 GOG 264 Chemo naive primary or recurrent sex cord/ stromal tumors of the ovary Randomized phase II Carboplatin/paclitaxel vsbep Sample size: N= patients
7
8 Prospective Bevacizumab Trials Relapsed Ovarian Cancer Study Treatment Prior Treatment Setting Efficacy 6-mo PFS ORR GOG 170-D* [n=63] Single agent BV 15 mg/kg q 3 wk Relapsed platinum disease, up to 2 prior regimens 40% 18% NCI 5789** [n=70] BV 10 mg/kg q 2 wks + low dose oral cytoxan Relapsed platinum disease w/ postplatinum maximum of 2 regimens 56% 24% ORBIT*** [n = 44] Single agent BV 15 mg/kg q 3 wk Platinum, and Doxil/topo resistant, up to 3 regimens total 28% 16% GIP 0 2 [3%] 5 [11%] *R Burger et al., ASCO, J Clin Oncol 2007;25:5165 **A Garcia et al., ASCO, J Clin Oncol 2008;26:76 ***S Cannistra et al., ASCO, J Clin Oncol 2007;25:5180 GOG-251: A Phase II Trial Of Bevacizumab For Recurrent Sex Cord-Stromal Tumors Of The Ovary STUDY CHAIR STUDY: Jubilee Brown, M.D. M.D. Anderson Cancer Center SCHEMA: Bevacizumab 15 mg/kg IV Repeat every 21 days until disease progression or adverse effects prohibit further treatment 1. PRIMARY OBJECTIVE: To estimate the anti-tumor activity of bevacizumab by assessing frequency of objective response in patients with recurrent sex cordstromal tumors of the ovary who have measurable disease. 2. SECONDARY OBJECTIVES: To determine the nature and degree of toxicity in these patients. To determine the overall survival and progression-free survival of these patients. 3. TRANSLATIONAL RESEARCH OBJECTIVE: To quantify expression of angiogenic or lymphangiogenic markers in recurrent stromal tumors of the ovary to determine the frequency of alterations and potential utility of biologic agents directed at these proteins for inclusion in future studies.
9 Challenges?. Neumann Safety x Efficacy x PFS OS. Cost med. III cost $72,576 $401,088 per PF- Eisenhauer LYS On the basis of today s results, I Need OS data believe the use of bevacizumab in QoL data standard clinical practice may be ICON-7 premature. Who Decides? Investigators? PJ. National survey of oncologists. Health Aff (Millwood). 2010;29:196. Survival time required for new Rx that cost $70K 45% said 2-4 months $280K >> K per QALY. Patients?? Treasury? Insurance NCCN? Co? ASCO? Avastin May Extend PFS In Ovarian Cancer Patients Media? the cancer drug Avastin [bevacizumab] extends progressionfree survival by 39% in ovarian cancer patients." extended Avastin treatment, it took a median of 14.1 months for the cancer to start worsening, compared with 10.3 months Avastin can help fight relapsed ovarian cancer, this is the first" study "to show it also combats newly diagnosed disease, Burger says." SUMMARY Antiangiogenics Bevacizumab is a great drug Bevacizumab is not for everyone Bevacizumab is going to be the test of cost-effectiveness Richard T Penson MD MRCP rpenson@partners.org
Current state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationHow to fight a silent killer: Lessons learned from Ovarian Cancer. Stephen A. Cannistra, M.D.
How to fight a silent killer: Lessons learned from Ovarian Cancer Stephen A. Cannistra, M.D. How to fight a silent killer: Lessons learned from Ovarian Cancer Ovarian cancer is not common but is highly
More informationBackground. TAP, Paclitaxel + Doxorubicin + Cisplatin
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationState of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011
State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center Ovarian Cancer 21,880 new cases
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationGCIG Rare Tumor Working Group Report. David M. Gershenson Isabelle Ray-Coquard
GCIG Rare Tumor Working Group Report David M. Gershenson Isabelle Ray-Coquard Thursday 31 st May 2012 Ted Trimble IRCI - Aims To facilitate the development of international clinical trials of treatments
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationLUNG. Tumour Group: Regimen name / acronym. Place in therapy. Induction chemotherapy. Regimen name / acronym. Place in therapy
Tumour Group: LUNG Non-small cell lung cancer Adjuvant Vinorelbine PO* / Cisplatin 1 x x First line Vinorelbine IV / Cisplatin x First line Vinorelbine IV / Carboplatin x cisplatin Vinorelbine PO* / Cisplatin
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationPrincipal changes in clinical trials involving patients with Ovarian Cancer
Verona, 18.01.2019 Principal changes in clinical trials involving patients with Ovarian Cancer Principal changes in clinical trials involving patients with Ovarian Cancer Agenda 1. Patients: Biomarker
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationPrinciples of clinical management of ovarian cancer
Review Article on Neoadjuvant Therapy for Ovarian Cancer Page 1 of 5 Principles of clinical management of ovarian cancer Tatiana V. Gorodnova 1, Anna P. Sokolenko 2, Ekatherina Kuligina 2, Igor V. Berlev
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationWhere Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationGYNECOLOGICAL CANCERS
SAMO FoROMe Post ESMO 17 th October 2014, Bern GYNECOLOGICAL CANCERS Cristiana Sessa Oncology Institute of Southern Switzerland Bellinzona CONTENT Antiangiogenics in cervical cancer Antiangiogenics and
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationRTWG - Carcinosarcoma. Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza
RTWG - Carcinosarcoma Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza Overview Background Questions urgent and timely investigations? Proposed Approach Regulatory Solutions Output Carcinosarcomas Background
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationA stratified clinical approach to uterine sarcoma
A stratified clinical approach to uterine sarcoma Martee L. Hensley, MD Memorial Sloan-Kettering Cancer Center Gynecologic Medical Oncology Weill Cornell Medical College New York, NY USA Disclosure slide
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationOvarian cancer in elderly women
Ovarian cancer Ovarian cancer in elderly women Claire FALANDRY, Michel FABBRO, Olivier GUERIN, Jean-Emmanuel KURTZ, Anne LESOIN. Problem Background Population on the rise and extremely heterogeneous Delayed
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationSlide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationChemotherapy in Gynecologic Malignancies
Chemotherapy in Gynecologic Malignancies Dr U.D.Bafna Professor & Head, Department of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bangalore Chemotherapy in solid tumors is mainly adjuvant
More informationTHERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X
THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationA Pan HDAC Inhibitor with Clinical Potential in both Hematological Malignancies and Solid Tumors
A Pan HDAC Inhibitor with Clinical Potential in both Hematological Malignancies and Solid Tumors Discovery On Target Conference HDAC Inhibitors Dr Steven Butcher, TopoTarget Dr Richard Penson, Massachusetts
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More information